Disruptive Pharma AB (FRA:5LH0) Other Current Receivables: €0.51 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5LH0 Disruptive Pharma AB FRA:5LH0
4 GF Score
Price €0.09
View Full Analysis

What is Disruptive Pharma AB Other Current Receivables?

Disruptive Pharma AB FRA:5LH0 -0.92% 4 Other Current Receivables is €0.51 Mil as of Jun. 2026. GuruFocus rates FRA:5LH0 with a GF Score™ of 4/100.

Disruptive Pharma AB's Other Current Receivables for the quarter that ended in Jun. 2026 was €0.51 Mil.

Disruptive Pharma AB's quarterly Other Current Receivables declined from Dec. 2025 (€0.40 Mil) to Mar. 2026 (€0.36 Mil) but then increased from Mar. 2026 (€0.36 Mil) to Jun. 2026 (€0.51 Mil).

Disruptive Pharma AB's annual Other Current Receivables increased from Dec. 2023 (€0.13 Mil) to Dec. 2024 (€0.14 Mil) and increased from Dec. 2024 (€0.14 Mil) to Dec. 2025 (€0.40 Mil).

Disruptive Pharma AB Other Current Receivables Related Terms

Disruptive Pharma AB Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Disruptive Pharma AB's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Disruptive Pharma AB Other Current Receivables Chart

Disruptive Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.14 0.13 0.14 0.40

Disruptive Pharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.10 0.40 0.36 0.51
FRA:5LH0
4GF Score
Disruptive Pharma AB FRA:5LH0
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Disruptive Pharma AB Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0.51 Mil mean?
Disruptive Pharma AB (FRA:5LH0) has a Other Current Receivables of €0.51 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Disruptive Pharma AB and its competitors.
Is Disruptive Pharma AB's Other Current Receivables too high?
Disruptive Pharma AB's current Other Current Receivables is €0.51 Mil. Overall, Disruptive Pharma AB has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Disruptive Pharma AB's Other Current Receivables compare to ?
Disruptive Pharma AB's Other Current Receivables of €0.51 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Disruptive Pharma AB and its competitors. Disruptive Pharma AB's current Other Current Receivables is €0.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Disruptive Pharma AB stock overvalued right now?
Disruptive Pharma AB (FRA:5LH0) has a current Other Current Receivables of €0.51 Mil. The current Other Current Receivables is €0.51 Mil. Disruptive Pharma AB's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Disruptive Pharma AB (FRA:5LH0), the current Other Current Receivables is €0.51 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Disruptive Pharma AB Business Description

Comparable Companies
Other Exchanges DPHA:Sweden
Address Dag Hammarskjold Road 54B, Uppsala Science Park, Uppsala, SWE, 752 37
Disruptive Pharma AB is a Swedish drug delivery technology company developing and commercializing Formulite, a patented platform based on mesoporous magnesium carbonate (MMC). The platform is designed to improve the solubility, oral bioavailability and other properties of pharmaceutical compounds. The company's business model is based on contract development, partnerships and licensing arrangements with pharmaceutical and biotechnology companies for the development and commercialization of drug products optimized with Formulite.
4GF Score

Get the complete analysis for FRA:5LH0

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.09
Price